Mankind Pharma Ltd.
NSE: MANKINDMankind Pharma Ltd.: A 30-second snapshot
Mankind Pharma (₹2,462.2) trades at a trailing PE of 58.09 against a forward PE of 41.98, above both its 50-day (₹2,178.7) and 200-day (₹2,295.9) moving averages, with RSI at 70.94. The stock is up 18.27% over 3 months but only 2.28% over 12 months, sitting 9.33% below its 52-week high. Debt-to-equity stands at 53.89 with a rising debt trend, and quality score of 36 ranks 4th of 6 pharma-sector peers.
P/E
58.1
Forward P/E
42.0
ROE
—
Debt / Equity
53.89
Profit Margin
+12.8%
Div. Yield
+0.1%
5Y ROE > 15%
3/5
5Y FCF > 0
3/5
Quality
52/100
News
8 headlines · 2 positive · 0 negative
Mankind Pharma Announces Investor Conference Call for Q4FY26 on May 20 - scanx.trade
scanx.trade
Mankind Pharma Completes Interest Payment and Full Redemption of Non-Convertible Debentures Worth ₹12,50,00,00,000 - scanx.trade
scanx.trade
Mankind Pharma launches 'Act at 30' campaign focused on early heart screening - IMPACT Magazine
IMPACT Magazine
Mankind Pharma Ltd rises for third straight session - Business Standard
Business Standard
Mankind Pharma Ltd up for fifth session - Business Standard
Business Standard
Recent context
- ·Mankind Pharma has scheduled an investor conference call for Q4FY26 results on May 20, 2026, which will be the next material disclosure event for earnings trajectory and debt position.
- ·The stock rose for five consecutive sessions through May 15, 2026, according to Business Standard, coinciding with broader market activity rather than any stock-specific fundamental announcement in the news corpus.
- ·The company launched the Act at 30 cardiovascular screening campaign in May 2026, indicating continued consumer-health brand investment alongside its branded-generics core business.
Strengths
- +Forward PE of 41.98 represents a 27.7% compression versus trailing PE of 58.09, reflecting an implicit consensus expectation of meaningful earnings acceleration in the coming period.
- +Revenue has grown at a 5-year CAGR of 10.4%, demonstrating sustained top-line expansion in a sector where pricing power is subject to regulatory controls.
- +The stock completed full redemption of ₹1,250 crore in non-convertible debentures in April 2026, eliminating that specific liability from the balance sheet.
- +Current price of ₹2,462.2 is 13.0% above SMA-50 and 7.2% above SMA-200, with identified technical support levels at ₹2,217, ₹2,146.2, and ₹2,033.
Weaknesses
- −Earnings CAGR of 4.8% over 5 years lags revenue CAGR of 10.4% over the same period, indicating that margin pressure or rising costs have diluted top-line growth into bottom-line returns.
- −Debt-to-equity of 53.89 with a rising debt trend places leverage at an elevated level; ROE data is unavailable, limiting assessment of whether debt is generating commensurate returns.
- −Quality score of 36 ranks 4th of 6 in the peer group; ROE exceeded 15% in only 3 of the available historical years and FCF was positive in only 3 years, pointing to inconsistent capital efficiency.
- −Trailing PE of 58.09 is the second-highest among listed peers (CIPLA: 29.84, DRREDDY: 26.56, SUNPHARMA: 41.32), with no analyst consensus rating available in the data to triangulate that premium.
Open questions
- ?Does the gap between 5-year revenue CAGR (10.4%) and earnings CAGR (4.8%) reflect structural margin compression, one-time cost items, or rising R&D and brand-building investment — and is that trajectory changing?
- ?How does Mankind Pharma's debt-to-equity of 53.89 with a rising debt trend compare to the leverage profile of pure-play branded-generics peers, and what does the post-NCD-redemption balance sheet look like heading into Q4FY26?
- ?Given that the forward PE of 41.98 implies consensus expects earnings acceleration, what specific product launches, geographic expansions, or cost improvements are expected to drive that step-change versus the 5-year 4.8% CAGR baseline?
- ?RSI at 70.94 and a 18.27% 3-month gain follow an extended period of near-flat 12-month returns — what fundamental catalyst, if any, is cited by management or institutional holders to explain the timing of the recent move?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| MANKIND | Mankind Pharma Ltd.You're viewing | 58.1 | — | 36 |
| Industry avg | across 5 peers | 47.0 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.6 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.6 | +11.8% | 17 |
Technical state
Current price
₹2,462.20
SMA 50
₹2,178.70
SMA 200
₹2,295.90
RSI (14)
70.9 (overbought)
From 52w high
-9.3%
1Y return
+2.3%
3M return
+18.3%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- mediumDebt-to-equity of 53.89 with a rising debt trend warrants monitoring; though Mankind completed full redemption of NCDs worth ₹1,250 crore in April 2026, the absolute leverage level remains well above typical pharma-manufacturer norms.
- mediumQuality score of 36 ranks 4th of 6 peers in the sector (below MAXHEALTH at 54 and SUNPHARMA at 50); ROE exceeded 15% in only 3 of the years available, and FCF was positive in only 3 of those years, indicating inconsistent capital returns.
- mediumRSI of 70.94 is in overbought territory; the stock is up 18.27% over the past 3 months while the 1-year price change is only 2.28%, suggesting the recent rally compressed a prolonged flat-to-negative prior period into a short window.
- low5-year earnings CAGR of 4.8% materially lags 5-year revenue CAGR of 10.4%, indicating that revenue gains have not translated proportionally into bottom-line growth over the period.
- lowNews corpus is sparse (8 articles, 0 negative, 6 neutral); sentiment signal may not be representative of broader institutional or sector-specific coverage.
Cross-section contradictions
- Trailing PE of 58.09 is the second-highest among the 6 peers listed, yet quality score (36) and earnings CAGR (4.8%) are below sector median, suggesting the premium valuation is not currently supported by peer-relative profitability metrics.
- The stock has risen 18.27% over 3 months and trades above both SMA-50 (₹2,178.7) and SMA-200 (₹2,295.9), yet the 1-year price return is only 2.28%, implying the near-term surge follows an extended period of flat or negative performance.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 15 May 2026 · rotates through NIFTY 500 every ~5 days